Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Oertel SH, et al. Among authors: riess hb. Transplantation. 2000 Feb 15;69(3):430-2. doi: 10.1097/00007890-200002150-00021. Transplantation. 2000. PMID: 10706055
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Trappe RU, et al. Transplantation. 2007 Dec 27;84(12):1708-12. doi: 10.1097/01.tp.0000295987.12996.19. Transplantation. 2007. PMID: 18165786
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network. Trappe R, et al. Lancet Oncol. 2012 Feb;13(2):196-206. doi: 10.1016/S1470-2045(11)70300-X. Epub 2011 Dec 13. Lancet Oncol. 2012. PMID: 22173060 Clinical Trial.
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
Zimmermann H, Weiland T, Nourse JP, Gandhi MK, Reinke P, Neuhaus R, Karbasiyan M, Gärtner B, Anagnostopoulos I, Riess H, Trappe RU, Oertel S. Zimmermann H, et al. J Immunol Res. 2014;2014:264723. doi: 10.1155/2014/264723. Epub 2014 Feb 10. J Immunol Res. 2014. PMID: 24741582 Free PMC article. Clinical Trial.
333 results